Actinium Pharmaceuticals (ATNM) 10-K 11 Mar 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Mar. 10, 2016	Jun. 30, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	Actinium Pharmaceuticals, Inc.
Entity Central Index Key	1,388,320
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-K
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 102,508,000
Entity Common Stock, Shares Outstanding		44,391,097

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current Assets:
Cash and cash equivalents	$ 25,643,273	$ 6,706,802
Restricted cash - current	34,733
Prepaid expenses and other current assets	803,463	$ 699,851
Total Current Assets	26,481,469	7,406,653
Property and equipment, net of accumulated depreciation	$ 106,112	127,700
Restricted cash		34,733
Total Assets	$ 26,587,581	7,569,086
Current Liabilities:
Accounts payable and accrued expenses	1,473,936	2,283,796
Accounts payable and accrued expenses - related parties	25,000	214,357
Notes payable	265,695	283,552
Derivative liabilities	2,848,902	6,709,911
Total Current Liabilities	4,613,533	9,491,616
Total Liabilities	$ 4,613,533	$ 9,491,616
Commitments and contingencies
Stockholders' Equity (Deficit):
Preferred stock, $0.001 par value; 50,000,000 authorized, 0 shares issued and outstanding
Common stock, $0.001 par value; 200,000,000 shares authorized; 44,066,541 and 29,971,839 shares issued and outstanding, respectively	$ 44,067	$ 29,972
Additional paid-in capital	134,160,059	89,252,262
Accumulated deficit	(112,230,078)	(91,204,764)
Total Stockholders' Equity (Deficit)	21,974,048	(1,922,530)
Total Liabilities and Stockholders' Equity (Deficit)	$ 26,587,581	$ 7,569,086

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2015	Dec. 31, 2014
Balance Sheets [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	44,066,541	29,971,839
Common Stock, shares outstanding	44,066,541	29,971,839

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Statements of Operations [Abstract]
Revenue
Operating expenses:
Research and development, net of reimbursements	$ 13,311,739	$ 12,267,313	$ 3,109,331
General and administrative	11,464,560	10,175,323	3,476,879
Depreciation expense	$ 53,465	$ 37,908	1,560
Loss on disposition of equipment			4,122
Total operating expenses	$ 24,829,764	$ 22,480,544	6,591,892
Loss from operations	(24,829,764)	(22,480,544)	(6,591,892)
Other income (expense):
Interest expense	(7,868)	(866)	(2,508)
Gain (loss) on change in fair value of derivative liabilities	3,812,318	(2,206,099)	(4,179,392)
Total other income (expense)	3,804,450	(2,206,965)	(4,181,900)
Net loss	$ (21,025,314)	$ (24,687,509)	$ (10,773,792)
Net loss per common share - basic and diluted	$ (0.55)	$ (0.90)	$ (0.47)
Weighted average common shares outstanding - basic and diluted	38,158,480	27,363,748	22,752,752

Consolidated Statement of Chang

Consolidated Statement of Changes in Stockholders' Equity (Deficit) - USD ($)	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Beginning Balance at Dec. 31, 2012	$ 1,145,635	$ 21,392	$ 56,867,706	$ (55,743,463)
Beginning Balance, Shares at Dec. 31, 2012		21,391,665
Stock-based compensation	657,812	$ 265	657,547
Stock-based compensation, Shares		265,834
Proceeds from the sale of common stock, net of offering costs	2,883,257	$ 554	2,882,703
Proceeds from the sale of common stock, net of offering costs, Shares		554,310
Issuance of common stock from exercise of options	13,053	$ 17	13,036
Issuance of common stock from exercise of options, Shares		16,650
Issuance of common stock from exercise of warrants	3,467,395	$ 2,337	3,465,058
Issuance of common stock from exercise of warrants, Shares		2,336,988
Transfer of warrant derivatives from liability to equity classification	1,047,095		$ 1,047,095
Net loss	(10,773,792)			$ (10,773,792)
Ending Balance at Dec. 31, 2013	(1,559,545)	$ 24,565	$ 64,933,145	$ (66,517,255)
Ending Balance, Shares at Dec. 31, 2013		24,565,447
Stock-based compensation	6,280,629	$ 381	6,280,248
Stock-based compensation, Shares		379,901
Proceeds from the sale of common stock, net of offering costs	15,435,305	$ 2,380	15,432,925
Proceeds from the sale of common stock, net of offering costs, Shares		2,379,433
Issuance of common stock from exercise of options	275,153	$ 310	274,843
Issuance of common stock from exercise of options, Shares		310,400
Issuance of common stock from exercise of warrants	159,994	$ 2,336	157,658
Issuance of common stock from exercise of warrants, Shares		2,336,658
Direct costs incurred before shares are issued	(30,000)		(30,000)
Transfer of warrant derivatives from liability to equity classification	2,203,443		2,203,443
Net loss	(24,687,509)			$ (24,687,509)
Ending Balance at Dec. 31, 2014	(1,922,530)	$ 29,972	89,252,262	$ (91,204,764)
Ending Balance, Shares at Dec. 31, 2014		29,971,839
Stock-based compensation	7,061,622	$ 345	7,061,277
Stock-based compensation, Shares		344,784
Proceeds from the sale of common stock, net of offering costs	37,637,959	$ 11,994	37,625,965
Proceeds from the sale of common stock, net of offering costs, Shares		11,993,641
Issuance of common stock from exercise of options	15,680	$ 20	15,660
Issuance of common stock from exercise of options, Shares		20,000
Issuance of common stock from exercise of warrants	157,940	$ 1,736	156,204
Issuance of common stock from exercise of warrants, Shares		1,736,277
Transfer of warrant derivatives from liability to equity classification	48,691		48,691
Net loss	(21,025,314)			$ (21,025,314)
Ending Balance at Dec. 31, 2015	$ 21,974,048	$ 44,067	$ 134,160,059	$ (112,230,078)
Ending Balance, Shares at Dec. 31, 2015		44,066,541

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash Flows From Operating Activities:
Net loss	$ (21,025,314)	$ (24,687,509)	$ (10,773,792)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Stock-based compensation expense	7,061,622	6,280,629	657,812
Depreciation expense	$ 53,465	$ 37,908	1,560
Loss on disposition of equipment			4,122
Loss (gain) on change in fair value of derivative liabilities	$ (3,812,318)	$ 2,206,099	4,179,392
(Increase) decrease in:
Prepaid expenses and other current assets	162,083	(193,894)	106,579
Increase (decrease) in:
Accounts payable and accrued expenses	(793,949)	1,874,841	(518,089)
Accounts payable and accrued expenses - related party	(189,357)	133,172	50,000
Net Cash Used In Operating Activities	$ (18,543,768)	(14,348,754)	$ (6,292,416)
Cash Flows From Investing Activities:
Restricted cash		(34,733)
Purchase of property and equipment	$ (47,788)	(151,688)	$ (16,592)
Net Cash Used In Investing Activities	(47,788)	(186,421)	(16,592)
Cash Flows From Financing Activities:
Payments on note payable	(283,552)	(161,841)	(140,000)
Sales of stock, net of offering costs	37,637,959	15,435,305	2,883,257
Proceeds from the exercise of options	15,680	275,153	13,053
Proceeds from the exercise of warrants	157,940	159,994	3,467,395
Net Cash Provided By Financing Activities	37,528,027	15,708,611	6,223,705
Net change in cash	18,936,471	1,173,436	(85,303)
Cash at beginning of year	6,706,802	5,533,366	5,618,669
Cash at end of year	25,643,273	6,706,802	5,533,366
Supplemental disclosures of cash flow information:
Cash paid for interest	$ 7,868	$ 866	$ 561
Cash paid for taxes
Supplemental disclosure of non-cash investing and financing activities:
Stock issuance costs included in accounts payable and accrued expenses		$ 30,000
Insurance prepaid through premium finance	$ 265,695	$ 287,568	$ 157,825
Fair value of warrants issued with stock	4,738,161
Transfer from derivative liability classification to equity classification	$ 48,691	$ 2,203,443	$ 1,047,095

Description of Business and Sum

Description of Business and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Description of Business and Summary of Significant Accounting Policies [Abstract]
Description of Business and Summary of Significant Accounting Policies	Note 1 – Description of Business and Summary of Significant Accounting Policies Nature of Business - On December 28, 2012, the Company entered into a transaction (the “Share Exchange”), pursuant to which the Company acquired 100% of the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (“API”), in exchange for the issuance of approximately 99% of the issued and outstanding common stock, par value $0.001 per share, of the Company. As a result of the Share Exchange, the Company was then considered a holding company operating through API, a clinical-stage biopharmaceutical company developing certain cancer treatments. On March 20, 2013, the Company’s subsidiary, Actinium Pharmaceuticals, Inc., changed its name to Actinium Corporation. On April 11, 2013, the Company changed its domicile from the State of Nevada to the State of Delaware and changed its name from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc. On September 25, 2013, in accordance with a Certificate of Ownership Merging Actinium Corporation into the Actinium Pharmaceuticals, Inc. filed in Delaware, the Company merged (the “Merger”) into itself Actinium Corporation (a 93.7% owned subsidiary), and Actinium Corporation ceased to exist. As a result of the Merger, Actinium Corporation stock owned by the Company was cancelled and each share of Actinium Corporation not owned by the Company was exchanged for 0.333 shares of Company’s common stock. A total of 3,970,137 shares of Actinium Corporation common stock was exchanged for 1,322,055 shares of Company common stock. Principles of Consolidation - Use of Estimates in Financial Statement Presentation - Reclassification - Cash and Cash Equivalents - Property and Equipment - Impairment of Long-Lived Assets - Derivatives - Fair Value of Financial Instruments - Level 1 Inputs - Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2 Inputs - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means. Level 3 Inputs - Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity's own assumptions about the assumptions that market participants would use in pricing the assets or liabilities. The following tables set forth assets and liabilities measured at fair value on a recurring and non-recurring basis by level within the fair value hierarchy as of December 31, 2015 and 2014. As required by ASC 820 “ Fair Value Measurements and Disclosures” Level 1 Level 2 Level 3 Total Derivative liabilities: At December 31, 2015 - - $ 2,848,902 $ 2,848,902 At December 31, 2014 - - $ 6,709,911 $ 6,709,911 Income Taxes - Research and Development Costs – Share-Based Payments – Earnings (Loss) Per Common Share – December 31, December 31, December 31, Options 3,971,583 3,013,084 1,985,384 Warrants 8,954,031 7,634,058 9,673,290 Total 12,925,614 10,647,142 11,658,674 Recent Accounting Pronouncements Subsequent Events

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions	Note 2 – Related Party Transactions MSKCC: On February 11, 2002, the Company entered into a License, Development and Commercialization Agreement with Sloan-Kettering Institute of Cancer Research (“SKI”), an entity related to MSKCC, a majority shareholder of the Company. The agreement was amended in August 2006. Pursuant to the agreement, the Company licensed certain intellectual property from SKI, including critical patents with respect to the Company’s core technology that also supports ongoing research and clinical development of related drug candidates. MSKCC agreed, subject to certain conditions, to utilize the funds paid for certain clinical and preclinical programs and activities related to the Company’s drug development and clinical study programs, including the payment of certain costs and expenses that would otherwise have been borne by the Company. The Company is obligated to make the following milestone payments: Milestones Payments (1) filing of an New Drug Application (“NDA”) or regulatory approval for each licensed product $ 750,000 (2) upon the receipt of regulatory approval from the U.S. FDA for each licensed product 1,750,000 Under the agreement, the Company shall pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire. For the years ended December 31, 2015, 2014 and 2013, the annual maintenance fee and third party costs incurred was $0.2 million, $0.3 million and $0.1 million, respectively. As of December 31, 2015 and 2014, the Company has a payable to MSKCC covering the annual maintenance costs, clinical trials expense and patent costs totaling $0 and $0.2 million, respectively. On December 21, 2015, Actinium entered into an investor rights agreement with MSKCC. Under the terms of the agreement, MSKCC has agreed to forebear from transferring or otherwise disposing of its approximately 5.7 million shares of the Company’s common stock (other than pursuant to a piggyback registration as described below) until the start of the Actimab-A Phase 2 clinical study (but, in no event until later than March 31, 2016). Thereafter MSKCC shall be permitted to sell its shares subject to a weekly volume limitation of 150,000 shares (which limit may be increased to up to 250,000 shares per week to the extent any prior weekly allotments are not fully used) and applicable law so long as MSKCC maintains at least 25% of its current shareholding in Actinium through December 31, 2016. Actinium has granted MSKCC piggyback registration rights that would be triggered in the event Actinium are to engage in a public registered offering of its shares for its own account where other shareholders are participating as selling shareholders or where such public registered offering is for the account of other selling shareholders. In addition, following December 31, 2016, Actinium has granted MSKCC unlimited Form S-3 registration rights with respect to its shares. Placement Agent: On December 9, 2013, the Company entered into an engagement agreement with a Healthcare Investment Bank (“Placement Agent”) as its placement agent for the 2013 Common Stock Offering whereby a director of the Company was the former Head of its Healthcare Investment Banking team (“the 2013 Offering”). The 2013 Offering was completed in two tranches, December 9, 2013 and January 10, 2014. The agreement entered in on December 9, 2013 included a cash fee equal to 10% of the gross proceeds raised, a non-accountable expense reimbursement equal to 2% of the gross proceeds raised and warrants to purchase shares of the Company’s Common Stock in an amount equal to 10% of the shares of common stock issued or issuable. Subsequent to the closing of the 2013 Offering, the placement agent continued to provide certain financial advisory services to the Company until three months after the Company had up-listed its securities for trading on a U.S. National Exchange for a monthly fee of $25,000. On May 28, 2014, the Company and the placement agent agreed to terminate the December 9, 2013 engagement agreement. As of December 31, 2015 and 2014, the Company owed its placement agent $25,000. For the years ended December 31, 2014 and 2013, the placement agent received a cash fee of $397,303 and $399,103, respectively, from the 2013 Offering and was issued warrants to purchase 68,976 and 69,289 shares, respectively, of the Company’s Common Stock at $9 per share for a period of 5 years. On July 10, 2014, the Company completed another public offering pursuant to a shelf registration statement previously filed where the placement agent acted as lead manager. The placement received a cash fee of $455,108. On February 11, 2015, the Company completed a public offering that totaled 4,444,444 common shares, representing gross proceeds of approximately $20.0 million and a net amount of approximately $18.5 million after deducting the underwriting discount and the other offering expenses. The Placement Agent acted as the sole book-running manager for the offering. The offering was made pursuant to a shelf registration statement previously filed with and declared effective by the U.S. Securities and Exchange Commission. The Placement Agent received a cash fee of approximately $1.4 million. On June 9, 2015, the Company completed a registered direct offering of $5.0 million of its common stock. Under the terms of the subscription agreements, the Company issued an aggregate of 1,923,078 shares of the Company's common stock at a purchase price of $2.60 per share. The Placement Agent acted as the sole placement agent with respect to the offering. The Placement Agent received a cash fee of approximately $0.4 million.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2015
Prepaid Expenses and Other Current Assets [Abstract]
Prepaid Expenses and Other Current Assets	Note 3 – Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following at December 31, 2015 and 2014: December 31, December 31, 2015 2014 Security deposit $ - $ 11,350 Prepaid insurance 376,906 368,223 Other prepaid expenses 426,557 320,278 Total $ 803,463 $ 699,851

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2015
Property and Equipment [Abstract]
Property and Equipment	Note 4 – Property and Equipment Property and equipment consisted of the following at December 31, 2015 and 2014: December 31, December 31, Lives 2015 2014 Lab equipment 3 years $ 116,070 $ 108,713 Office equipment 3 years 82,974 58,455 Less: accumulated depreciation (92,932 ) (39,468 ) Property and equipment, net $ 106,112 $ 127,700 Depreciation expense for the years ended December 31, 2015, 2014 and 2013 was $53,465, $37,908 and $1,560, respectively. The Company wrote off certain undepreciated property and equipment during the year ended December 31, 2013 and recorded a loss of $4,122 on the disposition.

Note Payable

Note Payable	12 Months Ended
	Dec. 31, 2015
Note Payable [Abstract]
Note Payable	Note 5 – Note Payable On October 25, 2014, the Company entered into a premium finance agreement for its multiple commercial insurance policies in the amount of $43,075. Pursuant to the agreement, the Company was required to pay $4,882 in monthly installments for nine months. On December 28, 2014, the Company entered into a premium finance agreement for its director and officer liability insurance policy in the amount of $0.2 million. Pursuant to the agreement, the Company was required to pay $27,614 in monthly installments for nine months. As of December 31, 2015, the Company paid the agreements in full. On December 28, 2015, the Company entered into a premium finance agreement for its director and officer liability insurance policy in the amount of $0.3 million. Pursuant to the agreement, the Company was required to pay $30,077 in monthly installments for nine months. As of December 31, 2015 and 2014, the outstanding balance related to the premium finance agreements was $0.3 million.

Derivatives

Derivatives	12 Months Ended
	Dec. 31, 2015
Derivatives [Abstract]
Derivatives	Note 6 – Derivatives The Company has determined that certain warrants the Company has issued contain provisions that protect holders from future issuances of the Company’s common stock at prices below such warrants’ respective exercise prices and these provisions could result in modification of the warrants’ exercise price based on a variable that is not an input to the fair value of a “fixed-for-fixed” option as defined under FASB ASC Topic No. 815 - 40. The warrants granted in connection with the issuance of the 2012 Common Stock Offering, and the placement agent warrants contain anti-dilution provisions that provide for a reduction in the exercise price of such warrants in the event that future common stock (or securities convertible into or exercisable for common stock) is issued (or becomes contractually issuable) at a price per share (a “Lower Price”) that is less than the exercise price of such warrant at the time. The amount of any such adjustment is determined in accordance with the provisions of the warrant agreement and depends upon the number of shares of common stock issued (or deemed issued) at the Lower Price and the extent to which the Lower Price is less than the exercise price of the warrant at the time. Activities for derivative warrant instruments during the years ended December 31, 2015 and 2014 were as follows: Shares subject to warrants Fair Value Balance, December 31, 2013 1,968,623 $ 6,707,255 Transfer from liability to equity classification (319,294 ) (2,203,443 ) Change in fair value - 2,206,099 Balance, December 31, 2014 1,649,329 6,709,911 Transfer from liability to equity classification (21,960 ) (48,691 ) Change in fair value - (3,812,318 ) Balance, December 31, 2015 1,627,369 $ 2,848,902 During the year ended December 31, 2015, 2,013,360 warrants were exercised, of which 21,960 were derivative warrants. The fair value of these derivative warrants totaling $48,691 were measured on the various exercise dates and reclassified to additional paid-in capital. During the year ended December 31, 2014, 2,501,993 warrants were exercised, of which 319,294 were derivative warrants.. The fair value of these derivative warrants totaling $2,203,443 were measured on various exercise dates and reclassified to additional paid-in capital. The fair values of the derivative warrants were calculated using a modified binomial valuation model with the following assumptions at each balance sheet date. December 31, December 31, 2015 2014 Market value of common stock on measurement date (1) $ 3.23 $ 5.89 Adjusted exercise price $ 2.48 $ 2.48 Risk free interest rate (2) 1.06 % 1.10 % Warrant lives in years 2.0 years 3.0 years Expected volatility (3) 87 % 71 % Expected dividend yield (4) - - Probability of stock offering in any period over 5 years (5) 100 % 100 % Offering price (6) $ 2.60 $ 4.50 (1) The market value of common stock at the above measurement dates is based on the Company’s trading price quoted on the NYSE MKT. (2) The risk-free interest rate was determined by management using the Treasury Bill rate as of the respective measurement date. (3) As of December 31, 2015, the volatility was estimated using the historical volatilities of the Company’s common stock traded in NYSE MKT market. As of December 31, 2014, the volatility was estimated using the historical volatilities of comparable companies in the same industry and region. (4) Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future. (5) Management determines the probability of future stock offering at each evaluation date. (6) Represents the estimated offering price in future offerings as determined by management.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies [Abstract]
Commitments and Contingencies	Note 7 – Commitments and Contingencies License and Research Agreements The Company has entered into license and research and development agreements with third parties under which the Company is obligated to make upfront payments as well as milestone and royalty payments. Notable inclusions in this category are: a. AbbVie Biotherapeutics Corp. – The Company entered into a Product Development and Patent License Agreement with AbbVie Biotherapeutics Corp. in 2003 to secure exclusive rights to a specific antibody when conjugated with alpha emitting radioisotopes. Upon execution of the agreement, the Company made a license fee payment of $3,000,000. The Company agreed to make milestone payments totaling $7,750,000 for the achievement of the following agreed to and contracted milestones: Milestones Payments (1) when Company initiates a Phase I Clinical Trial of a licensed product $ 750,000 (2) when Company initiates a Phase II Clinical Trial of a licensed product 750,000 (3) when Company initiates a Phase III Clinical Trial of a licensed product 1,500,000 (4) Biological License Application filing with U.S. FDA 1,750,000 (5) First commercial sale 1,500,000 (6) after the first $10,000,000 in net sales 1,500,000 Under the agreement, the Company shall pay to AbbVie Biotherapeutics Corp. on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire. The Company met its first milestone in 2012 and upon reaching the milestone the Company paid AbbVie Biotherapeutics Corp. a milestone payment of $750,000 on July 24, 2012. The milestone payment for the Phase 1 Clinical Trial was recorded as research and development expense. The Company has not initiated a Phase 2 Clinical Trial and no payment has been made to AbbVie Biotherapeutics Corp. since the July 24, 2012 payment. b. MSKCC – see Note 2 - Related Party Transactions. c. Oak Ridge National Laboratory (“ORNL”) – The Company is contracted to purchase radioactive material to be used for research and development, with a renewal option at the contract end. During the years ended December 31, 2015, 2014, and 2013, the Company purchased approximately $0.8 million, $0.6 million and $0.3 million, respectively, of radioactive material with ORNL. On December 21, 2015, the Company signed a contract with ORNL to purchase $0.9 million of radioactive material. d. Icon Clinical Research, LLC (formerly AptivSolutions) provides project management services for the study of the drug Ac-225-HuM195 (Actimab-A) used in the Company’s Phase 1 and Phase 2 clinical trials. The total project was estimated to cost approximately $1.9 million and required a 12.5% down payment of the total estimated project cost. The down payment totaling $0.2 million was paid in 2007 and 2012. On August 6, 2012, October 22, 2012 and May 16, 2013, the agreement was amended to provide for additional services. The total project is now estimated at approximately $2.7 million. AptivSolutions invoices the Company when services are rendered and the Company records the related expense to research and development expense. For the years ended December 31, 2015, 2014 and 2013, the Company incurred expenses of approximately $0.4 million, $0.4 million and $0.3 million, respectively, related to this agreement. e. On June 15, 2012, the Company entered into a license and sponsored research agreement with Fred Hutchinson Cancer Research Center (“FHCRC”) to build upon previous and ongoing clinical trials, with BC8 (licensed antibody). FHCRC has currently completed both a Phase 1 and Phase 2 clinical trial with BC8 and the Company intends to start preparation for a pivotal trial leading to an FDA approval. The Company has been granted exclusive rights to the BC8 antibody and related master cell bank developed by FHCRC. The cost to develop the trial will range from $13.2 million to $23.5 million, depending on the trial design as required by the FDA. Under the terms of the sponsored research agreement, the Company will fund the FHCRC lab with $0.2 million per year for the first two years and $0.3 million thereafter. Payments made toward funding the lab will be credited toward royalty payments owed to FHCRC in the given year. A milestone payment of $1 million will be due to FHCRC upon FDA approval of the first drug. Upon commercial sale of the drug, royalty payments of 2% of net sales will be due to FHCRC. f. On August 28, 2012, the Company entered into a clinical trial agreement with The University of Texas M.D. Anderson Cancer Center. The total estimated cost of conducting the clinical trial is approximately $0.5 million, which includes a non-refundable institutional fee of $14,500. The estimated cost is based on treating 24 patients through 2015. Upon execution of the agreement, the Company paid $33,946. During the years ended December 31, 2015 and 2014, the Company recorded an expense of approximately $0 and $0.1 million, respectively. g. On February 27, 2014, the Company entered into a manufacturing agreement with Goodwin Biotechnology Inc. ("Goodwin"). Goodwin oversees the current Good Manufacturing Practices (cGMP) production of a monoclonal antibody anticipated to be used in an upcoming phase 3 clinical trial of Iomab-B. Total cost of the agreement is $5.0 million. The Company made a non-refundable payment of $0.6 million upon execution of the agreement. Periodic payments will be made upon reaching certain milestones. As of December 31, 2015, the remaining cost of the agreement is approximately $1.5 million. Goodwin bills the Company when services are rendered and the Company records the related expense to research and development costs. For the years ended December 31, 2015 and 2014, the Company paid Goodwin approximately $4.2 million and $3.6 million, respectively. As of December 31, 2015 and 2014, the Company owed $0.1 million and $0.7 million, respectively, to Goodwin. h. On September 30, 2014, the Company entered into a research agreement with the Albert Einstein College of Medicine of Yeshiva University (“Einstein”). According to the agreement, Einstein will use certain materials provided by the Company to complete a research project. The research project will explore the feasibility of using Actinium 225 to prepare patients with blood borne cancers to receive a hematopoietic stem cell transplant. Einstein will periodically provide the Company with reports showing project data or research. The total fixed price of the project is $0.2 million which is payable to Einstein in three payments. During the years ended December 31, 2015 and 2014, the Company paid Einstein approximately $0.1 million. Lease Agreements On April 22, 2014, the Company entered into a sublease agreement for office space located at 379 Thornall Street, Edison, NJ. This agreement expires on September 30, 2016. The Company issued a letter of credit for $34,733 to the existing tenant and maintained a $34,733 certified deposit as collateral for the letter of credit. Future minimum obligations on the lease are: For the year ending December 31, 2016 $ 84,011

Equity

Equity	12 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Equity	Note 8 – Equity On December 9, 2013, the Company entered into an engagement agreement with its placement agent for the 2013 Common Stock Offering, (the “2013 Offering”) The 2013 Offering was completed in two tranches, on December 9, 2013 and January 10, 2014. On December 27, 2013, the Company completed the first sale of the 2013 Offering pursuant to a Unit Purchase Agreement, with certain accredited investors and pursuant to which: the investors agreed to purchase (i) an aggregate of 554,310 shares (the “Shares”) of common stock at $6.00 per share and (ii) five-year warrants to purchase an aggregate of 138,577 shares of common stock at an exercise price of $9.00 per share. The Company received $3.3 million in gross proceeds from the sale of securities and $2.9 million net proceeds after deducting the underwriting discount and the other offering expenses. The transaction date fair value of the warrants of $0.4 million was determined utilizing the Black-Scholes option pricing model utilizing the following assumptions: risk free interest rate – 0.07%, expected volatility – 84.06%, expected dividend yield - 0%, and a contractual life of 5 years. In January 2014, the Company completed the final tranche of the 2013 Offering and received approximately $3.3 million total gross proceeds from accredited investors (“2014 Closing”). The Company paid its placement agent total cash fees of approximately $0.4 million and paid attorney fees of $40,000 for their services resulting in net proceeds of $2.9 million. In the 2014 Closing, the Company sold 551,810 shares of common stock at $6.00 per share and granted 137,952 units of five-year warrants with an exercise price of $9.00 per share. The warrants are exercisable for a period of five years from the date of issuance. The transaction date fair value of the warrants of $0.6 million was determined utilizing the Black-Scholes option pricing model utilizing the following assumptions: risk free interest rate - 1.64%, expected volatility - 88%, expected dividend yield - 0%, and a contractual life of 5 years. During January 2014, in connection with the 2014 Closing, the Company issued the Placement Agent warrants to purchase an aggregate of 68,976 shares of common stock with an exercise price of $9.00 per share. The transaction date fair value of the warrants of $0.3 million was determined utilizing the Black-Scholes option pricing model utilizing the following assumptions: risk free interest rate – 1.64%, expected volatility - 88%, expected dividend yield - 0%, and a contractual life of 5 years. On March 24, 2014, the Company filed a shelf registration statement on Form S-3 (the “Registration Statement”) which was effective on April 17, 2014. This Registration Statement contained two prospectuses: (i) a base prospectus which covers the offering, issuance and sale by the Company of up to $200 million of its common stock, preferred stock, warrants and/or units; and (ii) a sales agreement prospectus covering the offering, issuance and sale by us of up to a maximum aggregate offering price of $75,000,000 of its common stock that may be issued and sold under a sales agreement (the “ Sales Agreement ” ) with MLV & Co. LLC ( “ MLV ” ) dated March 24, 2014. The Company will pay MLV in cash, upon the sale of common stock pursuant to the Sales Agreement, an amount equal to 3.0% of the gross proceeds from the sale of common stock. On April 28, 2014, the Company issued 500 shares and received net proceeds of $6,000 under the Sales Agreement with MLV. During the year ended December 31, 2015, the Company issued 5,626,119 common shares with an average price of $2.52 per share. The Company received $15.1 million gross proceeds ($14.7 million net proceeds) from the issuances. On June 30, 2014, the Company received gross proceeds of $12.5 million from a public offering of 1,670,000 shares of the Company’s common stock, $0.001 par value per share at a price to the public of $7.50 per share less underwriting discounts. The Company paid an underwriting discount of $0.9 million, paid other offering expenses of $0.1 million, and paid attorney and auditor fees of $0.1 million resulting in net proceeds of $11.5 million. Under the terms of the underwriting agreement, the Company also granted the underwriters a 30-day option to purchase up to an additional 250,000 shares of common stock to cover over-allotments, if any, at the offering price. On July 10, 2014, the underwriter exercised their over-allotment option to purchase an additional 157,123 shares from the Company for $7.50 per share. Including the exercise of the over-allotment option of $1.2 million, in gross proceeds, the Company’s June offering totaled 1,827,123 shares, representing gross proceeds of approximately $13.7 million and $12.6 million net after deducting the underwriting discount and other offering expenses. On February 11, 2015, the Company completed an underwritten offering of 4,444,444 shares of its common stock and warrants to purchase an aggregate of 3,333,333 shares of its common stock at a price to the public of $4.50 per share. The warrants will be exercisable for a period of 4 years at an exercise price of $6.50 per share and have a relative fair value of $3,540,659 on the issuance date. The Company received net proceeds of approximately $18.5 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by us, and excluding the underwriters’ over-allotment option. In addition, the Company granted the underwriters a 30-day option to purchase up to an additional 666,666 shares of common stock and warrants to purchase 499,999 shares of common stock solely to cover over-allotments, if any. The underwriter did not exercise the over-allotment option. On June 9, 2015, the Company closed a financing with certain investors in which it raised approximately $5,000,000 in gross proceeds or $4,480,000 in net proceeds, after deducting placement agent’s fees and other offering expenses. Investors purchased 1,923,078 shares of the Company’s common stock, at a price per share of $2.60. During the year ended December 31, 2015, the Company issued 1,532,124 common shares for the cashless exercise of warrants. During the year ended December 31, 2015, the Company also issued 224,153 common shares for $173,620 cash received from the exercise of options and warrants. During the year ended December 31, 2014, the Company issued 2,162,181 common shares for the cashless exercise of warrants. During the year ended December 31, 2014, the Company also issued 484,877 common shares for $435,147 cash received from the exercise of options and warrants. During the year ended December 31, 2013, the Company issued 235,158 common shares for cashless exercise of warrants. During the year ended December 31, 2013, the Company also issued 2,118,480 common shares for $3,480,448 cash received from the exercise of options and warrants. Approval of the 2013 Amended and Restated Stock Plan In September 2013, the Board of Directors of the Company approved the Company’s 2013 Stock Plan. The expiration date of the plan is September 9, 2023 and the total number of underlying shares of the Company’s common stock available for grant to employees, directors and consultants of the Company under the plan is 2,750,000 shares. In December 2015, the shareholders of the Company approved the second amendment to the plan and increased the number of shares authorized under the plan to 10,750,000 shares. Approval of the Equity Incentive Plan In September 2013, the Board approved the Company’s 2013 Equity Incentive Plan. The expiration date of the plan is September 9, 2023 and the total number of shares of the Company’s common stock available for grant to employees, directors and consultants of the Company under the plan is 450,000 shares. In December 2013, the shareholders of the Company approved the plan and increased the number of shares authorized under the plan to 1,000,000 shares. Restricted Stock During 2013, the Company granted employees, consultants and board members 312,500 shares of restricted stock. 80,000 shares of restricted stock vest 1 year from the grant date, 100,000 shares have a vesting period of 24 months. The remaining restricted shares granted are performance based and vest over time. The shares granted during the year ended December 31, 2013 were valued at $0.7 million based on the stock price on the grant dates. During the year ended December 31, 2014, the Company granted 633,041 shares of restricted stock and cancelled 50,000 shares of restricted stock. Of the total shares of restricted stock granted, 20,000 shares vest 3 months from the grant date, 30,374 shares vest 1 year from the grant date, 30,000 shares have a vesting period of 2 years, 202,497 shares have a vesting period of 4 years and 350,000 shares vest at the date of grant. The shares granted during the year ended December 31, 2014 were valued at $4.9 million based on the stock price on the grant dates. During the year ended December 31, 2015, the Company granted 479,651 shares of restricted common stock to consultants with a fair value of $2.3 million based on the stock price on the grant dates. Of the 479,651 restricted share awards granted in 2015, 329,651 shares vested at the date of grant and 150,000 shares vest over a six-month period. During the year ended December 31, 2015, the Company cancelled 126,265 shares of restricted stock originally granted to employees and issued a total of 152,499 options (see below). As a result of the cancellation of the 126,265 restricted shares, the Company recorded an expense of $0.8 million for the grant-date fair value of the restricted stock for which the requisite service is expected to be rendered. During the year ended December 31, 2015, 2014 and 2013, the Company recorded approximately $3.4 million, $3.7 million and $0.2 million, respectively, in stock-based compensation for all of the restricted shares outstanding. During the year ended December 31, 2015, the Company issued common shares totaling 344,784 for restricted shares granted in 2015 and prior years. Stock Options Following is a summary of option activities for the years ended December 31, 2015, 2014 and 2013: Number of Units Weighted Weighted Aggregate Outstanding, December 31, 2012 2,330,134 $ 0.96 8.91 $ 685,000 Issued 787,450 6.62 10.00 - Cancelled (1,115,550 ) 0.92 - - Exercised (16,650 ) 0.78 - - Outstanding, December 31, 2013 1,985,384 3.23 8.34 5,908,696 Issued 1,338,100 8.86 10.00 - Exercised (310,400 ) 0.95 - - Outstanding, December 31, 2014 3,013,084 5.98 8.35 4,728,842 Issued 1,554,499 2.78 10.00 - Cancelled (576,000 ) 8.70 - - Exercised (20,000 ) 0.78 - - Outstanding, December 31, 2015 3,971,583 4.34 8.01 2,964,146 Exercisable, December 31, 2015 1,826,741 3.56 7.37 2,024,556 During 2013, the Company granted employees and board members 787,450 options to purchase the Company’s common stock with exercise prices ranging from $3.60 to $6.70, a term of 10 years and vesting over a 4-year period. The fair value of $3.7 million was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 1.36% - 1.55% (2) expected life of 6 years, (3) expected volatility of 83.32% - 98.45%, and (4) zero expected dividends. During the year ended December 31, 2014, the Company granted employees, consultants, and its board members 1,338,100 options to purchase the Company’s common stock with exercise prices ranging from $0.78 to $11.95 and a term of 10 years with vesting over a 4-year period. The options have an aggregated fair value of $8.7 million that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 1.77% - 2.07% (2) expected life of 6 years, (3) expected volatility of 82.47% - 87.76%, and (4) zero expected dividends. During the year ended December 31, 2015, the Company granted employees, consultants, and its board members 1,554,499 options to purchase the Company’s common stock with exercise prices ranging from $1.79 to $3.58 and a term of 10 years with vesting period ranging from 1 to 4.17 years. The options have an aggregated fair value of $3.2 million that was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include: (1) discount rate of 1.56% - 1.91% (2) expected life of 6 years, (3) expected volatility of 85.01% - 94.89%, and (4) zero expected dividends. During the years ended December 31, 2015, 2014 and 2013, the Company received gross proceeds of $15,680, $0.3 million and $13,053 for exercise of options for 20,000 shares, 310,400 shares and 16,650 shares, respectively, of the Company’s common stock. All options issued and outstanding are being amortized over their respective vesting periods. The unrecognized compensation expense at December 31, 2015 and 2014 was $7.2 million and $10.2 million, respectively. During the years ended December 31, 2015, 2014 and 2013, the Company recorded option expense of $3.4 million, $2.4 million and $0.3 million, respectively. Warrants Following is a summary of warrant activities for the years ended December 31, 2015, 2014 and 2013: Number of Units Weighted Weighted Aggregate Outstanding, December 31, 2012 12,770,637 $ 0.97 4.48 $ 6,114,768 Granted 329,866 7.47 6.40 - Exercised (2,403,429 ) 1.58 - - Forfeited (1,023,784 ) - - - Outstanding, December 31, 2013 9,673,290 1.06 4.89 47,396,307 Granted 491,928 8.33 7.90 - Exercised (2,501,993 ) 0.67 - - Forfeited (29,167 ) 6.70 - - Outstanding, December 31, 2014 7,634,058 1.64 3.97 34,317,224 Granted 3,333,333 6.50 4.00 - Exercised (2,013,360 ) 0.41 - - Outstanding, December 31, 2015 8,954,031 3.73 2.93 10,199,230 Exercisable, December 31, 2015 8,669,031 3.59 2.75 10,199,230 During the year ended December 31, 2013, warrants to purchase 122,000 shares of common stock were granted to service providers at exercise prices ranging from $3.60 to $6.70 per share. These warrants have a term of 7 to 10 years and include (1) Warrants to purchase 72,000 shares of common stock vested immediately and were valued at $0.2 million on the grant date; and (2) Warrants to purchase 50,000 shares of common stock vest over a year and were valued at $0.2 million on the grant date. The fair value on the grant date was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include (1) discount rate of 1.36% - 1.55%, (2) expected term of 5 years, (3) expected volatility of 91.56%, and (4) zero expected dividends. As of December 31, 2013, unrecognized compensation expense related to the warrants was $0.2 million. During the year ended December 31, 2013, the Company also issued warrants to purchase 138,577 shares of the Company’s common stock to investors and warrants to purchase 69,289 shares of the Company’s common stock to its placement agent in connection with the 2013 Offering. During the year ended December 31, 2013, 2,403,429 warrants were exercised by the warrant holders. The Company issued 2,336,988 shares of common stock and received gross proceeds of approximately $3.5 million. During the year ended December 31, 2014, the Company granted warrants to purchase 137,952 shares of the Company’s common stock to investors and warrants to purchase 68,976 shares of the Company’s common stock to its placement agent in connection with the January 2014 Closing. During the year ended December 31, 2014, the Company also granted three consultants warrants to purchase 285,000 shares of the Company’s common stock with exercise prices ranging from $5.55 to $11.66 per share and a term of 10 years. These warrants vest when certain milestones are met. The fair value of the warrants was $2.1 million on the grant date and was calculated using the Black-Scholes option-pricing model. Variables used in the Black-Scholes option-pricing model include (1) discount rate of 1.56% - 1.66%, (2) expected term of 5 years, (3) expected volatility of 82.47-87.76%, and (4) zero expected dividends. As of December 31, 2014, unrecognized compensation expense related to the warrants was $1.5 million. During the year ended December 31, 2014, 2,501,993 warrants were exercised by the warrant holders. The Company issued 2,336,658 shares of common stock and received gross proceeds of $0.2 million. On February 11, 2015, the Company completed an underwritten offering of 4,444,444 shares of its common stock and warrants to purchase an aggregate of 3,333,333 shares of its common stock at a price of $4.50 per share. The warrants are exercisable for a period of 4 years at an exercise price of $6.50 per share. The transaction date relative fair value of the warrants of $3.5 million was determined utilizing the Black-Scholes option pricing model. Variables used in the Black-Scholes option-pricing model include (1) discount rate of 1.26%, (2) expected term of 4 years, (3) expected volatility of 72%, and (4) zero expected dividends. During the year ended December 31, 2015, 2,013,360 warrants were exercised by the warrant holders. The Company issued 1,736,277 shares of common stock and received gross proceeds of $0.2 million. During the year ended December 31, 2015, 2014 and 2013, the Company recorded stock-based compensation related to the warrants of $0.2 million, $0.1 million and $0.2 million, respectively.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Taxes [Abstract]
Income Taxes	Note 9 – Income Taxes Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets and liabilities at December 31, 2015 and 2014 are as follows: 2015 2014 Deferred tax assets: Net operating losses carry forward $ 28,910,183 $ 22,866,340 Less: valuation allowance (28,910,183 ) (22,866,340 ) Deferred tax assets, net $ - $ - As of December 31, 2015, for U.S. federal income tax reporting purposes, the Company has approximately $85.0 million of unused net operating losses (“NOLs”) available for carry forward to future years. The benefit from the carry forward of such NOLs will begin expiring during the year ended December 31, 2021. Because United States tax laws limit the time during which NOL carry forwards may be applied against future taxable income, the Company may be unable to take full advantage of its NOL for federal income tax purposes should the Company generate taxable income. Further, the benefit from utilization of NOLs carry forwards could be subject to limitations due to material ownership changes that could occur in the Company as it continues to raise additional capital. Based on such limitations, the Company has significant NOLs for which realization of tax benefits is uncertain. The difference between the income tax provision and the amount that would result if the U.S. Federal statutory rate of 34% were applied to pre-tax loss for the years ended December 31, 2015, 2014 and 2013 are as follows: For the year ended December 31, 2015 December 31, 2014 December 31, 2013 Federal income taxes at 34% $ (7,148,607 ) (34.00 )% $ (8,393,753 ) (34.00 )% $ (3,663,089 ) (34.00 )% Stock-based compensation 2,400,951 11.42 % 2,135,414 8.65 % 163,519 1.52 % Change in fair value of derivatives (1,296,188 ) (6.16 )% 750,073 3.04 % 1,420,993 13.19 % Other - - % 526,224 2.13 % - - % Change in valuation allowance 6,043,844 28.74 % 4,982,042 20.18 % 2,078,577 19.29 % Provision for income tax $ - - $ - - $ - -

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	Note 10 – Subsequent Events On January 4, 2016, the Company sold 40,656 shares of common stock for gross proceeds of $130,156 as part of the Sales Agreement with MLV. On January 22, 2016, 500 shares of restricted stock vested and the Company issued 500 shares of common stock to an employee. On January 27, 2016, the Company issued 114,169 shares of common stock for the conversion of 164,580 warrants. On February 16, 2016, the Company entered into a Service agreement with Medpace, Inc. where Medpace agreed to perform Phase 3 study of Iomab-B product. The study is scheduled to be finished in July 2018 with an estimated fees to Medpace of $6.6 million. On February 16, 2016, the Company issued 10,750 shares of common stock to a consultant with a fair value of $19,350. On February 22, 2016, 500 shares of restricted stock vested and the Company issued 500 shares of common stock to an employee. On February 29, 2016 the Company sold 15,946 shares of common stock for gross proceeds of $33,038 as part of the Sales Agreement with MLV. On March 3, 2016, the Company sold 82,557 shares of common stock for gross proceeds of $170,686 as part of the Sales Agreement with MLV. On March 4, 2016, the Company sold 21,109 shares of common stock for gross proceeds of $43,298 as part of the Sales Agreement with MLV. On March 7, 2016, the Company sold 38,369 shares of common stock for gross proceeds of $79,216 as part of the Sales Agreement with MLV.

Description of Business and S17

Description of Business and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Description of Business and Summary of Significant Accounting Policies [Abstract]
Nature of Business	Nature of Business - On December 28, 2012, the Company entered into a transaction (the “Share Exchange”), pursuant to which the Company acquired 100% of the issued and outstanding equity securities of Actinium Pharmaceuticals, Inc. (“API”), in exchange for the issuance of approximately 99% of the issued and outstanding common stock, par value $0.001 per share, of the Company. As a result of the Share Exchange, the Company was then considered a holding company operating through API, a clinical-stage biopharmaceutical company developing certain cancer treatments. On March 20, 2013, the Company’s subsidiary, Actinium Pharmaceuticals, Inc., changed its name to Actinium Corporation. On April 11, 2013, the Company changed its domicile from the State of Nevada to the State of Delaware and changed its name from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc. On September 25, 2013, in accordance with a Certificate of Ownership Merging Actinium Corporation into the Actinium Pharmaceuticals, Inc. filed in Delaware, the Company merged (the “Merger”) into itself Actinium Corporation (a 93.7% owned subsidiary), and Actinium Corporation ceased to exist. As a result of the Merger, Actinium Corporation stock owned by the Company was cancelled and each share of Actinium Corporation not owned by the Company was exchanged for 0.333 shares of Company’s common stock. A total of 3,970,137 shares of Actinium Corporation common stock was exchanged for 1,322,055 shares of Company common stock.
Principles of Consolidation	Principles of Consolidation -
Use of Estimates in Financial Statement Presentation	Use of Estimates in Financial Statement Presentation -
Reclassification	Reclassification -
Cash and Cash Equivalents	Cash and Cash Equivalents -
Property and Equipment	Property and Equipment -
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets -
Derivatives	Derivatives -
Fair Value of Financial Instruments	Fair Value of Financial Instruments - Level 1 Inputs - Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 2 Inputs - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These might include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (such as interest rates, volatilities, prepayment speeds, credit risks, etc.) or inputs that are derived principally from or corroborated by market data by correlation or other means. Level 3 Inputs - Unobservable inputs for determining the fair values of assets or liabilities that reflect an entity's own assumptions about the assumptions that market participants would use in pricing the assets or liabilities. The following tables set forth assets and liabilities measured at fair value on a recurring and non-recurring basis by level within the fair value hierarchy as of December 31, 2015 and 2014. As required by ASC 820 “ Fair Value Measurements and Disclosures” Level 1 Level 2 Level 3 Total Derivative liabilities: At December 31, 2015 - - $ 2,848,902 $ 2,848,902 At December 31, 2014 - - $ 6,709,911 $ 6,709,911
Income Taxes	Income Taxes -
Research and Development Costs	Research and Development Costs –
Share-Based Payments	Share-Based Payments –
Earnings (Loss) Per Common Share	Earnings (Loss) Per Common Share – December 31, December 31, December 31, Options 3,971,583 3,013,084 1,985,384 Warrants 8,954,031 7,634,058 9,673,290 Total 12,925,614 10,647,142 11,658,674
Recent Accounting Pronouncements	Recent Accounting Pronouncements
Subsequent Events	Subsequent Events

Description of Business and S18

Description of Business and Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Description of Business and Summary of Significant Accounting Policies [Abstract]
Summary of set forth liabilities measured at fair value on a recurring basis	Level 1 Level 2 Level 3 Total Derivative liabilities: At December 31, 2015 - - $ 2,848,902 $ 2,848,902 At December 31, 2014 - - $ 6,709,911 $ 6,709,911
Schedule of antidilutive securities excluded from computation of earnings per share	December 31, December 31, December 31, Options 3,971,583 3,013,084 1,985,384 Warrants 8,954,031 7,634,058 9,673,290 Total 12,925,614 10,647,142 11,658,674

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
Summary of activities related to related party	Milestones Payments (1) filing of an New Drug Application (“NDA”) or regulatory approval for each licensed product $ 750,000 (2) upon the receipt of regulatory approval from the U.S. FDA for each licensed product 1,750,000

Prepaid Expenses and Other Cu20

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2015
Prepaid Expenses and Other Current Assets [Abstract]
Summary of prepaid expenses and other current assets	December 31, December 31, 2015 2014 Security deposit $ - $ 11,350 Prepaid insurance 376,906 368,223 Other prepaid expenses 426,557 320,278 Total $ 803,463 $ 699,851

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2015
Property and Equipment [Abstract]
Summary of property and equipment	December 31, December 31, Lives 2015 2014 Lab equipment 3 years $ 116,070 $ 108,713 Office equipment 3 years 82,974 58,455 Less: accumulated depreciation (92,932 ) (39,468 ) Property and equipment, net $ 106,112 $ 127,700

Derivatives (Tables)

Derivatives (Tables)	12 Months Ended
	Dec. 31, 2015
Derivatives [Abstract]
Schedule of derivative warrant instruments activity	Shares subject to warrants Fair Value Balance, December 31, 2013 1,968,623 $ 6,707,255 Transfer from liability to equity classification (319,294 ) (2,203,443 ) Change in fair value - 2,206,099 Balance, December 31, 2014 1,649,329 6,709,911 Transfer from liability to equity classification (21,960 ) (48,691 ) Change in fair value - (3,812,318 ) Balance, December 31, 2015 1,627,369 $ 2,848,902
Summary of fair values of derivative warrants on basis of valuation model	December 31, December 31, 2015 2014 Market value of common stock on measurement date (1) $ 3.23 $ 5.89 Adjusted exercise price $ 2.48 $ 2.48 Risk free interest rate (2) 1.06 % 1.10 % Warrant lives in years 2.0 years 3.0 years Expected volatility (3) 87 % 71 % Expected dividend yield (4) - - Probability of stock offering in any period over 5 years (5) 100 % 100 % Offering price (6) $ 2.60 $ 4.50 (1) The market value of common stock at the above measurement dates is based on the Company’s trading price quoted on the NYSE MKT. (2) The risk-free interest rate was determined by management using the Treasury Bill rate as of the respective measurement date. (3) As of December 31, 2015, the volatility was estimated using the historical volatilities of the Company’s common stock traded in NYSE MKT market. As of December 31, 2014, the volatility was estimated using the historical volatilities of comparable companies in the same industry and region. (4) Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future. (5) Management determines the probability of future stock offering at each evaluation date. (6) Represents the estimated offering price in future offerings as determined by management.

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies [Abstract]
Summary of milestone payment	Milestones Payments (1) when Company initiates a Phase I Clinical Trial of a licensed product $ 750,000 (2) when Company initiates a Phase II Clinical Trial of a licensed product 750,000 (3) when Company initiates a Phase III Clinical Trial of a licensed product 1,500,000 (4) Biological License Application filing with U.S. FDA 1,750,000 (5) First commercial sale 1,500,000 (6) after the first $10,000,000 in net sales 1,500,000
Schedule of future minimum obligations on the lease	For the year ending December 31, 2016 $ 84,011

Equity (Tables)

Equity (Tables)	12 Months Ended
	Dec. 31, 2015
Warrants [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of option and warrant activities	Number of Units Weighted Weighted Aggregate Outstanding, December 31, 2012 12,770,637 $ 0.97 4.48 $ 6,114,768 Granted 329,866 7.47 6.40 - Exercised (2,403,429 ) 1.58 - - Forfeited (1,023,784 ) - - - Outstanding, December 31, 2013 9,673,290 1.06 4.89 47,396,307 Granted 491,928 8.33 7.90 - Exercised (2,501,993 ) 0.67 - - Forfeited (29,167 ) 6.70 - - Outstanding, December 31, 2014 7,634,058 1.64 3.97 34,317,224 Granted 3,333,333 6.50 4.00 - Exercised (2,013,360 ) 0.41 - - Outstanding, December 31, 2015 8,954,031 3.73 2.93 10,199,230 Exercisable, December 31, 2015 8,669,031 3.59 2.75 10,199,230
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary of option and warrant activities	Number of Units Weighted Weighted Aggregate Outstanding, December 31, 2012 2,330,134 $ 0.96 8.91 $ 685,000 Issued 787,450 6.62 10.00 - Cancelled (1,115,550 ) 0.92 - - Exercised (16,650 ) 0.78 - - Outstanding, December 31, 2013 1,985,384 3.23 8.34 5,908,696 Issued 1,338,100 8.86 10.00 - Exercised (310,400 ) 0.95 - - Outstanding, December 31, 2014 3,013,084 5.98 8.35 4,728,842 Issued 1,554,499 2.78 10.00 - Cancelled (576,000 ) 8.70 - - Exercised (20,000 ) 0.78 - - Outstanding, December 31, 2015 3,971,583 4.34 8.01 2,964,146 Exercisable, December 31, 2015 1,826,741 3.56 7.37 2,024,556

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Taxes [Abstract]
Components of deferred tax assets and liabilities	2015 2014 Deferred tax assets: Net operating losses carry forward $ 28,910,183 $ 22,866,340 Less: valuation allowance (28,910,183 ) (22,866,340 ) Deferred tax assets, net $ - $ -
Schedule of difference between the income tax provision and the U.S. Federal statutory rate	For the year ended December 31, 2015 December 31, 2014 December 31, 2013 Federal income taxes at 34% $ (7,148,607 ) (34.00 )% $ (8,393,753 ) (34.00 )% $ (3,663,089 ) (34.00 )% Stock-based compensation 2,400,951 11.42 % 2,135,414 8.65 % 163,519 1.52 % Change in fair value of derivatives (1,296,188 ) (6.16 )% 750,073 3.04 % 1,420,993 13.19 % Other - - % 526,224 2.13 % - - % Change in valuation allowance 6,043,844 28.74 % 4,982,042 20.18 % 2,078,577 19.29 % Provision for income tax $ - - $ - - $ - -

Description of Business and S26

Description of Business and Summary of Significant Accounting Policies (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Summary of liabilities measured at fair value on a recurring basis
Derivative liability	$ 2,848,902	$ 6,709,911
Level 1 [Member]
Summary of liabilities measured at fair value on a recurring basis
Derivative liability
Level 2 [Member]
Summary of liabilities measured at fair value on a recurring basis
Derivative liability
Level 3 [Member]
Summary of liabilities measured at fair value on a recurring basis
Derivative liability	$ 2,848,902	$ 6,709,911

Description of Business and S27

Description of Business and Summary of Significant Accounting Policies (Details 1) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	12,925,614	10,647,142	11,658,674
Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	3,971,583	3,013,084	1,985,384
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	8,954,031	7,634,058	9,673,290

Description of Business and S28

Description of Business and Summary of Significant Accounting Policies (Details Textual)	Dec. 28, 2012$ / shares	Sep. 25, 2013shares	Dec. 31, 2014$ / shares	Dec. 31, 2015$ / shares	Jun. 30, 2014$ / shares
Description of Business and Summary of Significant Accounting Policies (Textual)
Common stock, par value | $ / shares			$ 0.001	$ 0.001	$ 0.001
Machinery and equipment [Member]
Description of Business and Summary of Significant Accounting Policies (Textual)
Estimated useful lives			Three years
Furniture and fixtures [Member]
Description of Business and Summary of Significant Accounting Policies (Textual)
Estimated useful lives			Three years
Actinium [Member]
Description of Business and Summary of Significant Accounting Policies (Textual)
Percentage of ownership interest acquired by company	100.00%	93.70%
Common Stock issuable in consideration for equity interest acquisition	99.00%
Common stock, par value | $ / shares	$ 0.001
Shares received by each API shareholder of Actinium common stock for each API share exchanged		0.333
Common stock shares | shares		3,970,137
Common stock shares exchanged | shares		1,322,055

Related Party Transactions (Det

Related Party Transactions (Details) - Memorial Sloan Kettering Cancer Center [Member]	12 Months Ended
	Dec. 31, 2015USD ($)
New Drug Application [Member]
Summary of milestone payments related to related party
Milestones payments	$ 750,000
Receipt of Regulatory Approval From U.S. FDA [Member]
Summary of milestone payments related to related party
Milestones payments	$ 1,750,000

Related Party Transactions (D30

Related Party Transactions (Details Textual) - USD ($)

Feb. 22, 2016

Feb. 16, 2016

Jan. 22, 2016

Jun. 09, 2015

Feb. 11, 2015

Jul. 10, 2014

Jul. 10, 2014

Dec. 09, 2013

Jun. 30, 2014

Mar. 24, 2014

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2013

Related Party Transactions (Textual)

Underwritten offering common stock, Shares

1,670,000

5,626,119

Stock issued during period value under subscription agreements

$ 37,637,959

$ 15,435,305

$ 2,883,257

Gross proceeds from public offering

$ 12,500,000

15,100,000

Net proceeds from public offering

14,700,000

Sale of stock, Description

The Company will pay MLV in cash, upon the sale of common stock pursuant to the Sales Agreement, an amount equal to 3.0% of the gross proceeds from the sale of common stock. On April 28, 2014, the Company issued 500 shares and received net proceeds of $6,000 under the Sales Agreement with MLV.

Subsequent Event [Member]

Related Party Transactions (Textual)

Underwritten offering common stock, Shares

500

10,750

500

Stock issued during period value under subscription agreements

$ 19,350

Placement agent [Member]

Related Party Transactions (Textual)

Description of receivables of placement agent for services

The agreement entered in on December 9, 2013 included a cash fee equal to 10% of the gross proceeds raised, a non-accountable expense reimbursement equal to 2% of the gross proceeds raised and warrants to purchase shares of the Company's Common Stock.

Description of warrants receivables by placement

Warrants to purchase shares of the Company's Common Stock in an amount equal to 10% of the shares of common stock issued or issuable.

Monthly fee for financial advisory services

$ 25,000

Repayment of amount paid to placement agent

$ 25,000

25,000

Underwritten offering common stock, Shares

69,289

Cash fee

$ 455,108

$ 397,303

$ 399,103

Warrants to purchase of common stock

68,976

69,289

Exercise price of warrants

$ 9

Warrants term

5 years

Subscription Agreements [Member]

Related Party Transactions (Textual)

Amount paid to placement agent

$ 400,000

Underwritten offering common stock, Shares

1,923,078

Stock issued during period value under subscription agreements

$ 5,000,000

Share price

$ 2.60

IPO [Member]

Related Party Transactions (Textual)

Amount paid to placement agent

$ 1,400,000

Underwritten offering common stock, Shares

4,444,444

1,827,123

Gross proceeds from public offering

$ 20,000,000

$ 13,700,000

Net proceeds from public offering

$ 18,500,000

$ 12,600,000

$ 11,500,000

Exercise price of warrants

$ 6.50

MSKCC [Member]

Related Party Transactions (Textual)

Maintenance fees

$ 200,000

$ 300,000

$ 100,000

Royalty description

Under the agreement, the Company shall pay to MSKCC on a country-by-country basis a royalty of 2% of net sales of all licensed products until the later of: (1) 10 years from the first commercial sale, or (2) when the patents expire.

Number of shares common stock

5,700,000

Sale of stock, Description

Thereafter MSKCC shall be permitted to sell its shares subject to a weekly volume limitation of 150,000 shares (which limit may be increased to up to 250,000 shares per week to the extent any prior weekly allotments are not fully used) and applicable law so long as MSKCC maintains at least 25% of its current shareholding in Actinium through December 31, 2016.

MSKCC [Member] | Clinical Trial Agreement [Member]

Related Party Transactions (Textual)

Maintenance fees

$ 0

$ 200,000

Prepaid Expenses and Other Cu31

Prepaid Expenses and Other Current Assets (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Prepaid Expenses and Other Current Assets [Abstract]
Security deposit		$ 11,350
Prepaid insurance	$ 376,906	368,223
Other prepaid expenses	426,557	320,278
Total	$ 803,463	$ 699,851

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Summary of property and equipment
Less: accumulated depreciation	$ (92,932)	$ (39,468)
Property and equipment, net	$ 106,112	127,700
Lab equipment [Member]
Summary of property and equipment
Useful Lives	3 years
Property and equipment, gross	$ 116,070	108,713
Office equipment [Member]
Summary of property and equipment
Useful Lives	3 years
Property and equipment, gross	$ 82,974	$ 58,455

Property and Equipment (Detai33

Property and Equipment (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Property and Equipment (Textual)
Depreciation expense	$ 53,465	$ 37,908	$ 1,560
Loss on disposition of equipment			$ 4,122

Note Payable (Details)

Note Payable (Details)	Dec. 31, 2015USD ($)	Dec. 28, 2015USD ($)installments	Dec. 31, 2014USD ($)	Dec. 28, 2014USD ($)	Oct. 25, 2014USD ($)
Note Payable (Textual)
Outstanding balance related to premium finance agreements	$ 265,695		$ 283,552
Premium Finance Agreement [Member]
Note Payable (Textual)
Notes payable		$ 300,000		$ 200,000	$ 43,075
Amount required to pay in monthly installment		$ 30,077		$ 27,614	$ 4,882
Outstanding balance related to premium finance agreements	$ 300,000		$ 300,000
Number of installment | installments		9

Derivatives (Details)

Derivatives (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Schedule of derivative warrant instruments activity
Beginning balance, Shares subject to warrants	1,649,329	1,968,623
Transfer from liability to equity classification, Shares subject to warrants	$ (21,960)	$ (319,294)
Ending Balance, Shares subject to warrants	1,627,369	1,649,329
Beginning balance, Fair Value	$ 6,709,911	$ 6,707,255
Transfer from liability classification to equity classification, Fair Value	(48,691)	(2,203,443)
Change in fair value	(3,812,318)	2,206,099
Ending Balance, Fair Value	$ 2,848,902	$ 6,709,911

Derivatives (Details 1)

Derivatives (Details 1) - $ / shares		12 Months Ended
		Dec. 31, 2015	Dec. 31, 2014
Summary of fair values of derivative warrants on basis of valuation model
Market value of common stock on measurement date	[1]	$ 3.23	$ 5.89
Adjusted exercise price		$ 2.48	$ 2.48
Risk free interest rate	[2]	1.06%	1.10%
Warrant lives in years		2 years	3 years
Expected volatility	[3]	87.00%	71.00%
Expected dividend yield	[4]
Probability of stock offering in any period over 5 years	[5]	100.00%	100.00%
Offering price	[6]	$ 2.60	$ 4.50
[1]	The market value of common stock at the above measurement dates is based on the Company's trading price quoted on the NYSE MKT.
[2]	The risk-free interest rate was determined by management using the Treasury Bill rate as of the respective measurement date.
[3]	As of December 31, 2015, the volatility was estimated using the historical volatilities of the Company's common stock traded in NYSE MKT market. As of December 31, 2014, the volatility was estimated using the historical volatilities of comparable companies in the same industry and region.
[4]	Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.
[5]	Management determines the probability of future stock offering at each evaluation date.
[6]	Represents the estimated offering price in future offerings as determined by management.

Derivatives (Details Textual)

Derivatives (Details Textual) - USD ($)		12 Months Ended
		Dec. 31, 2015	Dec. 31, 2014
Derivatives (Textual)
Fair value of warrants			$ 2,100,000
Expected dividend yield	[1]
Warrant [Member]
Derivatives (Textual)
Number of warrants exercised		2,013,360	2,501,993
Derivative warrants		21,960	319,294
Fair value of warrants		$ 48,691	$ 2,203,443
Expected dividend yield		0.00%	0.00%
Probability of stock offering period		5 years	5 years
[1]	Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.

Commitments and Contingencies38

Commitments and Contingencies (Details) - AbbVie Biotherapeutics Corp [Member] - USD ($)	1 Months Ended	12 Months Ended
	Jul. 24, 2012	Dec. 31, 2015
Phase I Clinical Trial of a licensed product [Member]
Summary of milestone payment
Milestones payments	$ 750,000	$ 750,000
Phase II Clinical Trial of a licensed product [Member]
Summary of milestone payment
Milestones payments		750,000
Phase III Clinical Trial of a licensed product [Member]
Summary of milestone payment
Milestones payments		1,500,000
Biological License Application filing with U.S. FDA [Member]
Summary of milestone payment
Milestones payments		1,750,000
First Commercial Sale [Member]
Summary of milestone payment
Milestones payments		1,500,000
After First Net Sales [Member]
Summary of milestone payment
Milestones payments		$ 1,500,000

Commitments and Contingencies39

Commitments and Contingencies (Details 1)	Dec. 31, 2015USD ($)
Future minimum obligations on the lease are:
2,016	$ 84,011

Commitments and Contingencies40

Commitments and Contingencies (Details Textual)	Feb. 27, 2014USD ($)	Aug. 28, 2012USD ($)patients	Jul. 24, 2012USD ($)	Jun. 15, 2012USD ($)	Dec. 31, 2007USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Dec. 31, 2012USD ($)	Sep. 30, 2014USD ($)
Commitments and Contingencies (Textual)
Research recorded fees						$ 13,311,739	$ 12,267,313	$ 3,109,331
Security deposit							34,733
Letter of credit							34,733
Manufacturing Agreement [Member]
Commitments and Contingencies (Textual)
Project estimated cost for clinical trials of drug Ac-225-HuM195	$ 5,000,000					1,500,000
Non - refundable institutional fee	$ 600,000
Total project estimated to cost						100,000	700,000
Research and development costs						4,200,000	3,600,000
Einstein [Member]
Commitments and Contingencies (Textual)
Total project estimated to cost										$ 200,000
Research and development costs						100,000	100,000
AbbVie Biotherapeutics Corp [Member] | Product Development and Patent License Agreement [Member]
Commitments and Contingencies (Textual)
License fee payment						3,000,000
Milestones payments						$ 7,750,000
Description of royalty payment						Company shall pay to AbbVie Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.
Royalty of net sales percentage						12.00%
First commercial sale period						12 years 6 months
AbbVie Biotherapeutics Corp [Member] | After First Net Sales [Member]
Commitments and Contingencies (Textual)
Milestones payments						$ 1,500,000
AbbVie Biotherapeutics Corp [Member] | Phase I Clinical Trial of a licensed product [Member]
Commitments and Contingencies (Textual)
Milestones payments			$ 750,000			750,000
Abbott Biotherapeutics Corp [Member] | After First Net Sales [Member] | Product Development and Patent License Agreement [Member]
Commitments and Contingencies (Textual)
Net sales in milestones payment						10,000,000
Oak Ridge National Laboratory [Member]
Commitments and Contingencies (Textual)
Research and development costs						$ 800,000	600,000	300,000
Aptiv Solutions [Member]
Commitments and Contingencies (Textual)
Down payment of project estimated cost percentage						12.50%
Down payment for project					$ 200,000	$ 1,900,000			$ 200,000
Total project estimated to cost						2,700,000
Research and development costs						$ 400,000	400,000	300,000
Fred Hutchinson Cancer Research Center [Member] | license and sponsored research agreement [Member]
Commitments and Contingencies (Textual)
Milestones payments				$ 1,000,000
Description of royalty payment						Royalty payments of 2% of net sales will be due to FHCRC.
Royalty of net sales percentage				2.00%
Fund for Fred Hutchinson Cancer Research Center lab ( Per year for the first two years )				$ 200,000
Fund for Fred Hutchinson Cancer Research Center lab ( thereafter )				300,000
Research recorded fees						$ 300,000	200,000	$ 100,000
Fred Hutchinson Cancer Research Center [Member] | Maximum [Member] | license and sponsored research agreement [Member]
Commitments and Contingencies (Textual)
Clinical trial cost for approval of food and drug administration				23,500,000
Fred Hutchinson Cancer Research Center [Member] | Minimum [Member] | license and sponsored research agreement [Member]
Commitments and Contingencies (Textual)
Clinical trial cost for approval of food and drug administration				$ 13,200,000
University of Texas M.D. Anderson Cancer Center [Member] | Clinical Trial Agreement [Member]
Commitments and Contingencies (Textual)
Number of Patients | patients		24
Amount paid to each patient after Completing clinical trial		$ 500,000
Start-up fee for clinical trial		$ 33,946
Start-up due cost paid date		Dec. 31, 2015
Non - refundable institutional fee		$ 14,500
Research recorded fees						$ 100,000	$ 0

Equity (Details)

Equity (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Warrant [Member]
Summary of stock option/ warrant activities
Number of Units,Outstanding, Beginning balance	7,634,058	9,673,290	12,770,637
Issued/ Granted	3,333,333	491,928	329,866
Exercised	(2,013,360)	(2,501,993)	(2,403,429)
Cancelled/ Forfeited		(29,167)	(1,023,784)
Number of Units,Outstanding, Ending Balance	8,954,031	7,634,058	9,673,290
Exercisable	8,669,031
Weighted Average Exercise Price, Outstanding, Beginning balance	$ 1.64	$ 1.06	$ 0.97
Weighted Average Exercise Price, Issued/ Granted	6.50	8.33	7.47
Weighted Average Exercise Price, Exercised	0.41	0.67	1.58
Weighted Average Exercise Price, Forfeited/ Cancelled		6.70
Weighted Average Exercise Price, Outstanding, Ending Balance	3.73	$ 1.64	$ 1.06
Weighted Average Exercise Price, Exercisable	$ 3.59
Weighted Average Remaining Contractual Term (in years), Outstanding, Beginning balance	4 years	4 years 10 months 21 days	4 years 5 months 23 days
Weighted Average Remaining Contractual Term (in years), Issued/ Granted	3 years 1 month 13 days	7 years 10 months 24 days	6 years 4 months 24 days
Weighted Average Remaining Contractual Term (in years), Outstanding, Ending balance	2 years 11 months 5 days	3 years 11 months 19 days	4 years 10 months 21 days
Weighted Average Remaining Contractual Term (in years), Exercisable	2 years 9 months
Aggregate Intrinsic Value, Outstanding, Beginning balance	$ 34,317,224	$ 47,396,307	$ 6,114,768
Aggregate Intrinsic Value, Exercised
Aggregate Intrinsic Value, Outstanding, Ending Balance	10,199,230	$ 34,317,224	$ 47,396,307
Aggregate Intrinsic Value, Exercisable	$ 10,199,230
Stock Options [Member]
Summary of stock option/ warrant activities
Number of Units,Outstanding, Beginning balance	3,013,084	1,985,384	2,330,134
Issued/ Granted	1,554,499	1,338,100	787,450
Exercised	(20,000)	(310,400)	(16,650)
Cancelled/ Forfeited	(576,000)		(1,115,550)
Number of Units,Outstanding, Ending Balance	3,971,583	3,013,084	1,985,384
Exercisable	1,826,741
Weighted Average Exercise Price, Outstanding, Beginning balance	$ 5.98	$ 3.23	$ 0.96
Weighted Average Exercise Price, Issued/ Granted	2.78	8.86	6.62
Weighted Average Exercise Price, Exercised	0.78	0.95	0.78
Weighted Average Exercise Price, Forfeited/ Cancelled	8.70		0.92
Weighted Average Exercise Price, Outstanding, Ending Balance	4.34	$ 5.98	$ 3.23
Weighted Average Exercise Price, Exercisable	$ 3.56
Weighted Average Remaining Contractual Term (in years), Outstanding, Beginning balance	8 years 4 months 6 days	8 years 4 months 2 days	8 years 10 months 28 days
Weighted Average Remaining Contractual Term (in years), Issued/ Granted	10 years	10 years	10 years
Weighted Average Remaining Contractual Term (in years), Outstanding, Ending balance	8 years 4 days	8 years 4 months 6 days	8 years 4 months 2 days
Weighted Average Remaining Contractual Term (in years), Exercisable	7 years 4 months 13 days
Aggregate Intrinsic Value, Outstanding, Beginning balance	$ 4,728,842	$ 5,908,696	$ 685,000
Aggregate Intrinsic Value, Exercised
Aggregate Intrinsic Value, Outstanding, Ending Balance	2,964,146	$ 4,728,842	$ 5,908,696
Aggregate Intrinsic Value, Exercisable	$ 2,024,556

Equity (Details Textual)

Equity (Details Textual) - USD ($)		Jun. 09, 2015	Feb. 11, 2015	Jul. 10, 2014	Dec. 31, 2014	Jun. 30, 2014	Mar. 24, 2014	Jan. 31, 2014	Dec. 27, 2013	Sep. 30, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Equity (Textual)
Fair value assumptions, risk free interest rate	[1]										1.06%	1.10%
Fair value assumptions, expected volatility rate	[2]										87.00%	71.00%
Fair value assumptions, expected term											2 years	3 years
Fair value assumptions, expected dividend rate	[3]
Proceeds from the exercise of options											$ 15,680	$ 275,153	$ 13,053
Expense related to common stock granted											3,400,000	2,400,000	300,000
Unrecognized compensation expense					$ 10,200,000						7,200,000	$ 10,200,000
Gross proceeds from public offering						$ 12,500,000					15,100,000
Net proceeds from public offering											$ 14,700,000
Price per share						$ 7.50					$ 2.52
Common stock, par value					$ 0.001	$ 0.001					$ 0.001	$ 0.001
Common stock issued, shares						1,670,000					5,626,119
Proceeds from common stock issued											$ 37,637,959	$ 15,435,305	2,883,257
Underwriting discount									$ 2,900,000
Underwriting agreement description									Investors agreed to purchase (i) an aggregate of 554,310 shares (the “Shares”) of common stock at $6.00 per share and (ii) five-year warrants to purchase an aggregate of 138,577 shares of common stock at an exercise price of $9.00 per share. The Company received $3.3 million in gross proceeds from the sale of securities.
Registration statement description							This Registration Statement contained two prospectuses: (i) a base prospectus which covers the offering, issuance and sale by the Company of up to $200 million of its common stock, preferred stock, warrants and/or units; and (ii) a sales agreement prospectus covering the offering, issuance and sale by us of up to a maximum aggregate offering price of $75,000,000 of its common stock that may be issued and sold under a sales agreement (the “ Sales Agreement ” ) with MLV & Co. LLC ( “ MLV ” ) dated March 24, 2014.
Maximum offering price							75,000,000
Aggregate offering amount of securities sold to investors							The Company will pay MLV in cash, upon the sale of common stock pursuant to the Sales Agreement, an amount equal to 3.0% of the gross proceeds from the sale of common stock. On April 28, 2014, the Company issued 500 shares and received net proceeds of $6,000 under the Sales Agreement with MLV.
Proceeds from the sale of common stock, net of offering costs											$ 37,637,959	15,435,305	$ 2,883,257
Fair value of warrants												$ 2,100,000
Investor [Member]
Equity (Textual)
Warrants issued to purchase common stock, shares												137,952	138,577
Price per share		$ 2.60
Proceeds from common stock issued		$ 5,000,000
Proceeds from the sale of common stock, net of offering costs		5,000,000
Net proceeds from sale of stock		$ 4,480,000
Shares purchased by investors		1,923,078
Consultant [Member]
Equity (Textual)
Fair value assumptions, expected term												10 years
Warrants issued to purchase common stock, shares												285,000
Consultant [Member] | Minimum [Member]
Equity (Textual)
Exercise price of warrants					5.55							$ 5.55
Consultant [Member] | Maximum [Member]
Equity (Textual)
Exercise price of warrants					11.66							11.66
2013 Stock Plan [Member]
Equity (Textual)
Number of additional shares authorized											10,750,000
2013 Stock Plan [Member] | Employees, directors and consultants [Member]
Equity (Textual)
Number of stock option granted										2,750,000
Award expiration date										Sep. 9, 2023
2013 Equity Incentive Plan [Member]
Equity (Textual)
Number of additional shares authorized													1,000,000
2013 Equity Incentive Plan [Member] | Employees, directors and consultants [Member]
Equity (Textual)
Number of stock option granted										450,000
Award expiration date										Sep. 9, 2023
Placement agent [Member]
Equity (Textual)
Exercise price of warrants											$ 9
Common stock issued, shares													69,289
Placement agent cash fees								$ 400,000
Placement agent attorney fees								40,000
Net proceeds from sale of stock								3,300,000
Net proceeds from issuance of services								2,900,000
Warrant [Member]
Equity (Textual)
Fair value of warrants determined utilizing the Black-Scholes option pricing model								$ 600,000
Exercise price of warrants					$ 9							$ 9
Fair value assumptions, risk free interest rate								1.64%
Fair value assumptions, expected volatility rate								88.00%					91.56%
Fair value assumptions, expected term								5 years				5 years	5 years
Fair value assumptions, expected dividend rate								0.00%				0.00%	0.00%
Expense related to common stock granted											$ 200,000	$ 100,000	$ 200,000
Unrecognized compensation expense					$ 1,500,000							$ 1,500,000	$ 200,000
Price per share					$ 6							$ 6
Common stock issued, shares					551,810								122,000
Warrants/ Common stock granted					137,952
Warrants exercised by warrant holders											2,013,360	2,501,993	2,403,429
Warrants to purchase common stock vested, shares													72,000
Warrant to purchase common stock vested, value													$ 200,000
Warrants to purchase common stock expected to vest, shares													50,000
Warrants to purchase common stock expected to vest, value													$ 200,000
Term of warrants								5 years
Warrant [Member] | Minimum [Member]
Equity (Textual)
Exercise price of warrants													$ 3.60
Fair value assumptions, expected volatility rate												82.47%
Fair value assumptions, expected discount rate											1.56%	1.56%	1.36%
Term of warrants													7 years
Warrant [Member] | Maximum [Member]
Equity (Textual)
Exercise price of warrants													$ 6.70
Fair value assumptions, expected volatility rate												87.76%
Fair value assumptions, expected discount rate											1.91%	1.66%	1.55%
Term of warrants													10 years
Common Stock [Member]
Equity (Textual)
Common stock issued, shares											1,736,277	2,336,658	2,336,988
Proceeds from common stock issued											$ 200,000	$ 200,000	$ 3,500,000
Common Stock [Member] | Placement agent [Member]
Equity (Textual)
Fair value of warrants determined utilizing the Black-Scholes option pricing model								$ 300,000	$ 400,000
Exercise price of warrants								$ 9
Fair value assumptions, risk free interest rate								1.64%	0.07%
Fair value assumptions, expected volatility rate								88.00%	84.06%
Fair value assumptions, expected term								5 years	5 years
Fair value assumptions, expected dividend rate								0.00%	0.00%
Common stock issued, shares								68,976
Restricted Stock [Member]
Equity (Textual)
Number of shares of restricted stock, granted											344,784
Expense related to common stock granted											$ 3,400,000	$ 3,700,000	$ 200,000
Restricted Stock [Member] | Employees, directors and consultants [Member]
Equity (Textual)
Number of shares of restricted stock, granted											152,499	633,041	312,500
Restricted stock granted value											$ 800,000	$ 4,900,000	$ 700,000
Restricted stock granted not been issued												202,497
Number of stock option cancelled											126,265	50,000
Description restricted stock												Of the total shares of restricted stock granted, 20,000 shares vest 3 months from the grant date, 30,374 shares vest 1 year from the grant date, 30,000 shares have a vesting period of 2 years, 202,497 shares have a vesting period of 4 years and 350,000 shares vest at the date of grant.	80,000 shares of restricted stock vest 1 year from the grant date, 100,000 shares have a vesting period of 24 months. The remaining restricted shares granted are performance based and vest over time.
Restricted Stock [Member] | Consultant [Member]
Equity (Textual)
Number of shares of restricted stock, granted											479,651
Restricted stock granted value											$ 2,300,000
Restricted stock granted not been issued											329,651
Description restricted stock											Of the 479,651 restricted share awards granted in 2015, 329,651 shares vested at the date of grant and 150,000 shares vest over a six-month period.
Public Offering [Member]
Equity (Textual)
Exercise price of warrants			$ 6.50
Fair value assumptions, expected volatility rate			72.00%
Fair value assumptions, expected term			4 years
Fair value assumptions, expected dividend rate			0.00%
Fair value assumptions, expected discount rate			1.26%
Warrants issued to purchase common stock, shares			3,333,333
Number of additional stock option granted				157,123
Proceeds from the exercise of options				$ 1,200,000
Gross proceeds from public offering			$ 20,000,000	13,700,000
Net proceeds from public offering			$ 18,500,000	$ 12,600,000		$ 11,500,000
Price per share		$ 2.60	$ 4.50	$ 7.50
Common stock issued, shares			4,444,444	1,827,123
Underwriting discount				$ 12,600,000		$ 900,000
Underwriting agreement description			In addition, the Company granted the underwriters a 30-day option to purchase up to an additional 666,666 shares of common stock and warrants to purchase 499,999 shares of common stock solely to cover over-allotments, if any. The underwriter did not exercise the over-allotment option.			Under the terms of the underwriting agreement, the Company also granted the underwriters a 30-day option to purchase up to an additional 250,000 shares of common stock to cover over-allotments, if any, at the offering price.
Warrants/ Common stock granted			666,666
Other offering expenses						$ 100,000
Auditor fees						$ 100,000
Fair value of warrants			$ 3,500,000
Warrant One [Member]
Equity (Textual)
Common shares issued for cashless exercise of warrants											1,532,124	2,162,181	235,158
Additional common stock issued for exercise of options and warrants											224,153	484,877	2,118,480
Proceeds from stock options and warrants exercised											$ 173,620	$ 435,147	$ 3,480,448
Stock Option Plan [Member]
Equity (Textual)
Fair value of warrants determined utilizing the Black-Scholes option pricing model
Fair value assumptions, expected term											6 years	6 years	6 years
Fair value assumptions, expected dividend rate											0.00%	0.00%	0.00%
Number of stock option granted											1,554,499	1,338,100	787,450
Number of stock option cancelled											576,000		1,115,550
Share-based compensation term											10 years	10 years	10 years
Share-based Compensation vesting period												4 years	4 years
Fair value of stock option											$ 3,200,000	$ 8,700,000	$ 3,700,000
Stock option exercise prices											$ 0.78	$ 0.95	$ 0.78
Proceeds from the exercise of options											$ 15,680	$ 275,153	$ 13,053
Number of option exercised											20,000	310,400	16,650
Warrants/ Common stock granted													787,450
Stock Option Plan [Member] | Minimum [Member]
Equity (Textual)
Exercise price of warrants													$ 3.60
Fair value assumptions, expected volatility rate											85.01%	82.47%	83.32%
Fair value assumptions, expected discount rate											1.69%	1.77%	1.36%
Share-based Compensation vesting period											1 year
Stock option exercise prices											$ 1.79	$ 0.78
Stock Option Plan [Member] | Maximum [Member]
Equity (Textual)
Exercise price of warrants													$ 6.70
Fair value assumptions, expected volatility rate											94.89%	87.76%	98.45%
Fair value assumptions, expected discount rate											1.91%	2.07%	1.55%
Share-based Compensation vesting period											4 years 2 months 1 day
Stock option exercise prices											$ 3.58	$ 11.95
[1]	The risk-free interest rate was determined by management using the Treasury Bill rate as of the respective measurement date.
[2]	As of December 31, 2015, the volatility was estimated using the historical volatilities of the Company's common stock traded in NYSE MKT market. As of December 31, 2014, the volatility was estimated using the historical volatilities of comparable companies in the same industry and region.
[3]	Management determined the dividend yield to be 0% based upon its expectation that it will not pay dividends for the foreseeable future.

Income Taxes (Details)

Income Taxes (Details) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Deferred tax assets:
Net operating losses carry forward	$ 28,910,183	$ 22,866,340
Less: valuation allowance	$ (28,910,183)	$ (22,866,340)
Deferred tax assets, net

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Schedule of difference between the income tax provision and the U.S. Federal statutory rate
Federal income taxes at 34%	$ (7,148,607)	$ (8,393,753)	$ (3,663,089)
Federal income taxes at 34%, Percentage	(34.00%)	(34.00%)	(34.00%)
Stock-based compensation	$ 2,400,951	$ 2,135,414	$ 163,519
Stock-based compensation, Percentage	11.42%	8.65%	1.52%
Change in fair value of derivatives	$ (1,296,188)	$ 750,073	$ 1,420,993
Change in fair value of derivatives, Percentage	(6.16%)	3.04%	13.19%
Other		$ 526,224
Other, Percentage		2.13%
Change in valuation allowance	$ 6,043,844	$ 4,982,042	$ 2,078,577
Change in valuation allowance, Percent	28.74%	20.18%	19.29%
Provision for income tax
Provision for income tax, Percent

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Taxes (Textual)
Net operating losses (NOLs)	$ 85
Expiration date	Dec. 31, 2021
U.S. Federal statutory rate	(34.00%)	(34.00%)	(34.00%)

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	Mar. 07, 2016	Mar. 04, 2016	Mar. 03, 2016	Feb. 22, 2016	Feb. 16, 2016	Jan. 22, 2016	Jan. 04, 2016	Feb. 29, 2016	Jan. 27, 2016	Jun. 30, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Subsequent Events (Textual)
Common stock issued, shares										1,670,000	5,626,119
Proceeds from common stock issued											$ 37,637,959	$ 15,435,305	$ 2,883,257
Subsequent Event [Member]
Subsequent Events (Textual)
Common stock issued, shares				500	10,750	500
Proceeds from common stock issued					$ 19,350
Restricted stock vested shares									114,169
Conversion of warrants shares									164,580
Subsequent Event [Member] | Medpace, Inc. [Member]
Subsequent Events (Textual)
Estimated fees					$ 6,600,000
Subsequent Event [Member] | MLV [Member]
Subsequent Events (Textual)
Common stock issued, shares	38,369	21,109	82,557				40,656	15,946
Proceeds from common stock issued	$ 79,216	$ 43,298	$ 170,686				$ 130,156	$ 33,038
Subsequent Event [Member] | Restricted Stock [Member]
Subsequent Events (Textual)
Common stock issued, shares				500		500